SecBot SecBot
SC 13D/A ·Filed Nov 12, 2026

PDSB

PDS Biotechnology Corp
NEUTRAL
Impact 4/10
Horizonweeks Processed4d 20h ago SEC0001193125-26-456632
Activist stake amendment (position change)
Actionable Insight • Neutral

The warrant exercise is a procedural step that does not change the activist's economic exposure or strategic position. Watch for the Phase 3 protocol submission for PDS0301, which would trigger the $10 million milestone closing and potentially increase Nant Capital's stake further.

DirectionNeutral
Confidencehigh
Horizonweeks

Drugs in focus

PDSB drug pipeline →

PDS0301

◆ Mixed Named in this SC 13D/A
Impact
Phase
Phase 2
Time to market
PDS0301 is in Phase 2 clinical development for metastatic colorectal cancer. Assuming successful Phase 2 data and a clear regulatory path, a registrational Phase 3 trial would likely take several years, meaning potential approval is likely 4+ years away under optimistic assumptions.
Next catalyst
None dated

What to watchPDS0301 is now PDS Biotech's sole internally-funded asset after the company discontinued its Phase 3 PDS0101 program in August 2026. The next catalyst is Q3 2026 earnings on November 12, 2026, where management may provide updates on the PDS0301 Phase 2 development plan and cash runway. Beyond that, watch for the company to outline a registrational path for PDS0301 in mCRC with liver metastases, which could involve an End-of-Phase 2 FDA meeting. The stock trades near $1.03 with a mean analyst target of $4.50, implying significant upside if the Phase 2 data translates into a viable registration strategy.

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1
Entry
$0.9800
T+0 close · Nov 12, 2026 · via day close
Latest settled
−10.96%
T+1 · $0.8726
Vs SPY
−10.60%
α at T+1
Next horizon
T+5
in 2d
  1. T+0 · Nov 12 $0.9800entry
  2. T+1 · 4d ago −10.96%α −10.60% · $0.8726
  3. T+2 · todayOpen
  4. T+5 · in 2d Pending
  5. T+20 · in 24d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Nant Capital exercised its 17,699,115 Common Warrants in full, converting them into 9,851,119 shares of common stock and 7,847,996 Pre-Funded Warrants for an aggregate exercise price of $3.89 million. The stake remains at 19.9% due to a beneficial ownership blocker, and the Pre-Funded Warrants (30,240,892 total) are not exercisable within 60 days. The activist's board representation and option to negotiate an exclusive license for PDS0101 remain unchanged, and a $10 million milestone closing tied to a Phase 3 protocol submission for PDS0301 is still pending.

Key Financial Metrics

Stake
19.9%
Investor
Nant Capital, LLC / Patrick Soon-Shiong

Key Facts

  • Nant Capital exercised 17,699,115 Common Warrants on November 9, 2026, for $3,891,215.46.
  • Exercise converted into 9,851,119 common shares and 7,847,996 Pre-Funded Warrants.
  • Nant Capital now holds 22,856,453 common shares (19.9% of 114,856,548 outstanding) and 30,240,892 Pre-Funded Warrants.
  • All Pre-Funded Warrants are subject to a 19.9% beneficial ownership blocker and are not exercisable within 60 days.
  • No Common Warrants remain outstanding.
  • Board representation (two seats) and the PDS0101 option to negotiate remain in place.
  • A $10 million milestone closing is contingent on submission of a Phase 3 protocol for PDS0301 to the FDA.
  • No other transactions in common stock during the past 60 days.

Financial Impact

Nant Capital paid $3.89 million to exercise warrants; no new capital raised for the company beyond the initial PIPE. The $10 million milestone closing is still pending.

dilutionownership

Risk Factors

  • The Pre-Funded Warrants remain subject to a 19.9% blocker, limiting future dilution from this holder.
  • The company is pre-revenue with a history of dilutive offerings and cash burn, as noted in the prior 10-K.
  • The $10 million milestone closing is contingent on FDA protocol submission, which may be delayed or not occur.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
89% bullish (9 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
SC 13D/A Filing (Primary)0001193125-26-456632
Document: 0001193125-26-456632-index.html0001193125-26-456632
Document: 0001193125-26-456632.txt0001193125-26-456632

Track record

28 reports on PDSB

Performance horizon

7 of 14 bullish or bearish reports moved the stock their way by T+20. Best: +71.95% at T+20 after the Jul 22, 2026 report. 11 of 14 went positive at some point.

Filters
  1. Nov 13, 20263d ago Press Release Neutral 4/10 Entry $0.8726 Now $0.9240 +5.89% settles Dec 14
  2. Nov 12, 20264d ago SC 13D/A Neutral 4/10 Viewing Entry $0.9800 Now $0.9240 −5.71% settles Dec 11
  3. Nov 10, 20266d ago 8-K Neutral 4/10 Entry $1.03 Now $0.9240 −10.29% settles Dec 9
  4. Oct 20, 202627d ago 3 Neutral 2/10 Entry $1.24 Now $0.9240 −25.48% settles Nov 18
  5. Oct 20, 202627d ago 8-K Neutral 4/10 Entry $1.24 Now $0.9240 −25.48% settles Nov 18
  6. Oct 20, 202627d ago 8-K Neutral 3/10 Entry $0.9605 Now $0.9240 −3.80% settles Nov 17
  7. Oct 14, 20264w ago S-3 Bearish 7/10 Entry $1.30 to $0.9800 Now $0.9240 +28.92% ▲ +24.62% +22.71% vs SPY
  8. Oct 6, 20265w ago 8-K Neutral 3/10 Entry $1.05 to $1.41 Now $0.9240 −11.58% ▲ +34.93% +38.10% vs SPY
  9. Sep 22, 20267w ago 8-K Bullish 6/10 Entry $0.9100 to $0.9605 Now $0.9240 +1.54% ▲ +5.55% +6.11% vs SPY
  10. Sep 22, 20267w ago Press Release Bullish 7/10 Entry $0.9100 to $0.9605 Now $0.9240 +1.54% ▲ +5.55% +6.11% vs SPY
Showing 10 of 28

US Market Status

Market Closed · Opens in 6h 41m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 12, 2026